@jlevy2

Health economist @JohnsHopkinsSPH @JHSPH_HPM

 Baltimore, MD
publichealth.jhu.edu/faculty/3686/joseph-f-levy
Joined January 2011
  • Tweets367
  • Following1K
  • Followers532
19Media
Joe Levy retweeted
JAMA
@JAMA_currentJul 9
Nearly one-third of first-time #prescription attempts for single-source branded drugs in the US were rejected due to formulary exclusion or utilization management, with more than 48% resulting in no dispensed therapy in the same class within 90 days. ja.ma/4vnWIZg
1
10
1
16
5,097
We have a new paper in @JAMA_current documenting the now-ubiquitous nature of formulary management for brand drugs By 2024, 40% (!) of initial attempts to fill a brand drug were rejected for prior auth or formulary exclusion (most of the growth over time is more prior auth)
2
10
3
10
6,864
Under the IRA, Part D plans have responded to lower out-of-pocket limits with higher deductibles The result is a sharp "tilting" of OOP spending through the year. Average OOP costs for brand fills are now higher in January, but sharply lower in later months as people hit the cap
1
2
3
461
AHRQ-funded researchers calculated the US could save $150M every year by switching from low molecular weight heparin to aspirin for blood clot prevention in orthopedic trauma patients. (That grant cost <$100K.) pubmed.ncbi.nlm.nih.gov/4066…

Cost Savings of Switching to Aspirin for Thromboprophylaxis in Orthopaedic Trauma Patients: A...

Level 1, Economic.

pubmed.ncbi.nlm.nih.gov
1
2
3
430
Very interesting to get a deeper look at what Medicare coverage of the weight loss drugs might cost, taking into account existing rebates & considering the counterfactual that many are likely to gain coverage through other indications over time regardless.
Ben Ippolito@ben_ippolito15 Aug 2024
Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in @Health_Affairs (with @jlevy2) healthaffairs.org/doi/10.137…

Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Bill...

The introduction of highly effective anti-obesity drugs, such as Wegovy, has prompted debate over Medicare’s prohibition on coverage of such products. In this study, we estimated the costs of...

healthaffairs.org
1
5
1,399
Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in @Health_Affairs (with @jlevy2) healthaffairs.org/doi/10.137…

Expanding Medicare Coverage Of Anti-Obesity Medicines Could Increase Annual Spending By $3.1 Bill...

The introduction of highly effective anti-obesity drugs, such as Wegovy, has prompted debate over Medicare’s prohibition on coverage of such products. In this study, we estimated the costs of...

healthaffairs.org
4
22
6
63
55,994
And go.....
1
15
989
🚨 New publication alert 🚨 I am so excited to share that I published part of my dissertation work in JAMA HF. A huge thank you to these co-authors: @KellyAnders0n, @jlevy2, @healthecon_dan, and the twitterless Thomas V Johnson and Jerry Anderson jamanetwork.com/journals/jam…

Macular Degeneration Drug Prescribing Patterns After Step Therapy Introduction in Medicare Advantage

This retrospective encounter-based analysis evaluates the impact of step therapy on macular degeneration drug prescribing patterns among 3 large Medicare Advantage insurers.

jamanetwork.com
5
7
40
2,811
We've drafted a response to the recent CMS RFI on additional data collection to study the Medicare Advantage program. Want to sign on? Send me an email by Friday March 8th docs.google.com/document/d/1…

Response to RFI for MA Data Collection

If you would like to add your signature to this response, please email Kelly Anderson ([email protected]) with your name, title, and organization by Friday March 8th March XX, 2024 RE:...

docs.google.com
1
13
2
23
7,382
FDA approval of 2nd potent GLP-1 for treatment of obesity - Lilly’s drug Zepbound - will accelerate discounting as competition heats up, reducing costs and extending access to patients. A prior @AEIecon analysis captured magnitude of earlier discounts aei.org/wp-content/uploads/2…
8
2
53
35,117
Ozempic, Wegovy, and other GLP-1s perfectly illustrate the common (and large) gaps between list and net prices of many brand drugs. A summary of our work: "Ozempic and Wegovy Don’t Cost What You Think They Do" via @nytimes nytimes.com/2023/10/22/healt…

Ozempic and Wegovy Don’t Cost What You Think They Do (Published 2023)

Drug companies are making billions from a new class of in-demand weight-loss treatments. But the prices are not what they seem.

nytimes.com
1
2
1
4
1,024
Hmm: New @AEI study estimates huge #GrossToNetBubble for GLP-1 #drugs. Net prices far below list prices due to #PBM #rebates & manuf copay support 👇 Perhaps economic impact has been overestimated? Full report: drugch.nl/3tiWRCB
2
8
4
23
11,556
Now in print, @jlevy2 and I test whether coverage of brand drugs in Part D differs based on whether the drug is a "good" or "bad" value relative to cost-effectiveness estimates. In short, it does not. aei.org/research-products/wo…

Drug Pricing Decisions and Insurance Coverage: Evidence from Medicare Part D

This paper examines whether the pricing of brand drugs, relative to estimates of their clinical value, is related to the way insurers cover those products in Medicare Part D.

aei.org
1
3
7
1,558
Defining “the price” of brand drugs like Ozempic can be complex. Our white paper summarizes what we know about the prices of new treatments for diabetes and obesity Short story: Very big differences between list and net prices, even adjusting for coupons aei.org/research-products/re…

Estimating the Cost of New Treatments for Diabetes and Obesity

The rising popularity of drugs to treat obesity and diabetes, including Ozempic, has focused attention on their costs. However, existing research has incompletely characterized prices by focusing on...

aei.org
1
9
14
4,940
CMS will use comparative effectiveness to adjust the starting point in price negotiations, but how exactly? We adapted the French system (added benefit ratings linked to domestic reference prices) to model one approach and estimate savings. @jlevy2 valueinhealthjournal.com/art…

Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United...

US Medicare will begin negotiating prices for top-selling drugs in 2023. This study describes and estimates potential savings from a therapeutic reference pricing approach, linking comparative...

valueinhealthjournal.com
1
3
1
12
1,561
New paper out in @health_affairs In Medicare Advantage, less use of longitudinal home-based medical care but substantially greater use of one-time home-based medical visits (likely related to diagnosis coding) than in traditional Medicare healthaffairs.org/doi/full/1…

Home-Based Medical Care Use In Medicare Advantage And Traditional Medicare In 2018 | Health Affairs...

The use of home-based medical care differed in Medicare Advantage and traditional Medicare in 2018. Having exactly one such visit was thirty-one times as likely for Medicare Advantage beneficiaries...

healthaffairs.org
5
1
15
2,216
My new @NEJM Perspective with @SeanTunis: @CMSGov is becoming a major #HTA organization. It should embrace the role. tinyurl.com/3f56499a @TuftsCEVR @TuftsMedicalCtr @Arnold_Ventures @HTAiOrg @UW_Pharmacy @SchaefferCenter @DusetzinaS #heor @a_kaltenboeck @joeymattingly
1
27
1
47
8,722
Great morning discussing health care price transparency and patients out of pocket costs at #IHEA2023 @KellyAnders0n @Angela_HSR @Mark_Meiselbach @michalhorny @AssumeNormality @ashleyleech – at Cape Town, South Africa
6
3
28
4,297
Hey #ARM23 attendees, looking for one last session to close out an amazing few days? Check out this late-breaking session: “Medicare and Drug Pricing and Spending” today at 10:30am. Come learn about findings from the Transparency in Coverage insurance disclosed pricing data!
3
12
988
Load more